Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4Y5H

Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors

Summary for 4Y5H
Entry DOI10.2210/pdb4y5h/pdb
Related4Y46
DescriptorMitogen-activated protein kinase 10, 1-(trans-4-{[7-oxo-8-(propan-2-yl)-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}cyclohexyl)-3-propan-2-ylurea (3 entities in total)
Functional Keywordsjnk, map kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationCytoplasm : P53779
Total number of polymer chains1
Total formula weight42648.44
Authors
Park, H. (deposition date: 2015-02-11, release date: 2015-05-06, Last modification date: 2024-02-28)
Primary citationZheng, K.,Park, C.M.,Iqbal, S.,Hernandez, P.,Park, H.,LoGrasso, P.V.,Feng, Y.
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.
Acs Med.Chem.Lett., 6:413-418, 2015
Cited by
PubMed Abstract: A novel series of 2-aminopyridopyrimidinone based JNK (c-jun N-terminal kinase) inhibitors were discovered and developed. Structure-activity relationships (SARs) were systematically developed utilizing biochemical and cell based assays and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies. Through the optimization of lead compound 1, several potent and selective JNK inhibitors with high oral bioavailability were developed. Inhibitor 13 was a potent JNK3 inhibitor (IC50 = 15 nM), had high selectivity against p38 (IC50 > 10 μM), had high potency in functional cell based assays, and had high stability in human liver microsome (t 1/2 = 76 min), a clean CYP-450 inhibition profile, and excellent oral bioavailability (%F = 87). Moreover, cocrystal structures of compounds 13 and 22 in JNK3 were solved at 2.0 Å. These structures elucidated the binding mode (Type-I binding) and can pave the way for further inhibitor design of this pyridopyrimidinone scaffold for JNK inhibition.
PubMed: 25893042
DOI: 10.1021/ml500474d
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.055 Å)
Structure validation

237423

數據於2025-06-11公開中

PDB statisticsPDBj update infoContact PDBjnumon